Cannabis-Induced psychosis (CIP) - Epidemiology Forecast - 2032

January 2022 | 60 pages | ID: C3D19E96ACD3EN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Cannabis-Induced psychosis (CIP) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cannabis-Induced psychosis (CIP) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Cannabis-Induced psychosis (CIP) Understanding

The DelveInsight Cannabis-Induced psychosis (CIP) epidemiology report gives a thorough understanding of the Cannabis-Induced psychosis (CIP) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Cannabis-Induced psychosis (CIP) in the US, Europe, and Japan. The report covers the detailed information of the Cannabis-Induced psychosis (CIP) epidemiology scenario in seven major countries (US, EU5, and Japan).

Cannabis-Induced psychosis (CIP) Epidemiology Perspective by DelveInsight

The Cannabis-Induced psychosis (CIP) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Cannabis-Induced psychosis (CIP) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Cannabis-Induced psychosis (CIP) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Cannabis-Induced psychosis (CIP) Detailed Epidemiology Segmentation

The Cannabis-Induced psychosis (CIP) epidemiology covered in the report provides historical as well as forecasted Cannabis-Induced psychosis (CIP) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Cannabis-Induced psychosis (CIP) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Cannabis-Induced psychosis (CIP) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Cannabis-Induced psychosis (CIP) Epidemiology Report and Model provide an overview of the global trends of Cannabis-Induced psychosis (CIP) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Cannabis-Induced psychosis (CIP) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Cannabis-Induced psychosis (CIP)
• The report provides the segmentation of the Cannabis-Induced psychosis (CIP) epidemiology

Report Highlights

• 11-year Forecast of Cannabis-Induced psychosis (CIP) epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Cannabis-Induced psychosis (CIP)
• Cases of Cannabis-Induced psychosis (CIP) by Mutation Types
• Cannabis-Induced psychosis (CIP) Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Cannabis-Induced psychosis (CIP)?
• What are the key findings pertaining to the Cannabis-Induced psychosis (CIP) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Cannabis-Induced psychosis (CIP) across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Cannabis-Induced psychosis (CIP)?
• What are the currently available treatments of Cannabis-Induced psychosis (CIP)?

Reasons to buy

The Cannabis-Induced psychosis (CIP) Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Cannabis-Induced psychosis (CIP) market
• Quantify patient populations in the global Cannabis-Induced psychosis (CIP) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Cannabis-Induced psychosis (CIP) therapeutics in each of the markets covered
• Understand the magnitude of Cannabis-Induced psychosis (CIP) population by its epidemiology
• The Cannabis-Induced psychosis (CIP) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF CANNABIS-INDUCED PSYCHOSIS (CIP)

3. CANNABIS-INDUCED PSYCHOSIS (CIP): DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Cannabis-Induced psychosis (CIP) Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Cannabis-Induced psychosis (CIP) Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Cannabis-Induced psychosis (CIP) Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Cannabis-Induced psychosis (CIP) Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Cannabis-Induced psychosis (CIP) Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Cannabis-Induced psychosis (CIP) Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Cannabis-Induced psychosis (CIP) Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Cannabis-Induced psychosis (CIP) Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Cannabis-Induced psychosis (CIP) Treatment and Management
6.2. Cannabis-Induced psychosis (CIP) Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Cannabis-Induced psychosis (CIP) Epidemiology in 7MM (2019-2032)
Table 2: Cannabis-Induced psychosis (CIP) Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Cannabis-Induced psychosis (CIP) Epidemiology in the United States (2019-2032)
Table 4: Cannabis-Induced psychosis (CIP) Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Cannabis-Induced psychosis (CIP) Epidemiology in Germany (2019-2032)
Table 6: Cannabis-Induced psychosis (CIP) Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Cannabis-Induced psychosis (CIP) Epidemiology in France (2019-2032)
Table 8: Cannabis-Induced psychosis (CIP) Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Cannabis-Induced psychosis (CIP) Epidemiology in Italy (2019-2032)
Table 10: Cannabis-Induced psychosis (CIP) Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Cannabis-Induced psychosis (CIP) Epidemiology in Spain (2019-2032)
Table 12: Cannabis-Induced psychosis (CIP) Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Cannabis-Induced psychosis (CIP) Epidemiology in the United Kingdom (2019-2032)
Table 14: Cannabis-Induced psychosis (CIP) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Cannabis-Induced psychosis (CIP) Epidemiology in Japan (2019-2032)
Table 16: Cannabis-Induced psychosis (CIP) Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Cannabis-Induced psychosis (CIP) Epidemiology in 7MM (2019-2032)
Figure 2 Cannabis-Induced psychosis (CIP) Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Cannabis-Induced psychosis (CIP) Epidemiology in the United States (2019-2032)
Figure 4 Cannabis-Induced psychosis (CIP) Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Cannabis-Induced psychosis (CIP) Epidemiology in Germany (2019-2032)
Figure 6 Cannabis-Induced psychosis (CIP) Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Cannabis-Induced psychosis (CIP) Epidemiology in France (2019-2032)
Figure 8 Cannabis-Induced psychosis (CIP) Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Cannabis-Induced psychosis (CIP) Epidemiology in Italy (2019-2032)
Figure 10 Cannabis-Induced psychosis (CIP) Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Cannabis-Induced psychosis (CIP) Epidemiology in Spain (2019-2032)
Figure 12 Cannabis-Induced psychosis (CIP) Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Cannabis-Induced psychosis (CIP) Epidemiology in the United Kingdom (2019-2032)
Figure 14 Cannabis-Induced psychosis (CIP) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Cannabis-Induced psychosis (CIP) Epidemiology in Japan (2019-2032)
Figure 16 Cannabis-Induced psychosis (CIP) Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report